Novartis IP Expert Slams Rival's Royalties Estimate At Trial
During a California federal jury trial Monday over claims Novartis owes a Daiichi Sankyo subsidiary royalties for infringing its skin cancer patents, Novartis' patent damages expert criticized the unit's $47.2 million...To view the full article, register now.
Already a subscriber? Click here to view full article